Press Releases



SALT LAKE CITY and TORONTO, May 28, 2014 /PRNewswire/ —  EastGate Acquisitions Corporation (OTCBB:  ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules, announced today that it will be presenting at the SeeThruEquity 3rd Annual Investor Conference. The presentation will take place today at 3:00 p.m. in the Madison Hub Room.




Convene Grand Central

Room: Madison Hub

101 Park Avenue (at 41 Street)

New York, NY


SeeThruEquity Conferences are held approximately every 2 months throughout the year and are focused on an exciting list of microcap presenting companies. The conferences allow presenting companies’ management teams to access industry professionals and investors who are looking for new ideas, opportunities and corporate relationships.

“We look forward to our presentation today”, says Anna Gluskin, Chief Executive Officer of EastGate Acquisitions Corporation. “This conference provides us with a venue to showcase our platform technology and product pipeline relevant not only to the company’s pharmaceutical developments but to companies who could benefit from the application of our Self-Emulsifying Technology to enhance their own product line”, concludes Gluskin.

About EastGate Acquisitions Corporation

EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules.   The Company’s model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements.  Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules.  The Company’s product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes.   Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions.  EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development.  We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate’s approach will be most beneficial for patient care.   For more information, please visit the company’s website at

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.


The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT: Rose Perri 1-647-692-0652


Text: ESAQ to 87804

Leave a Reply

Your email address will not be published. Required fields are marked *